STAAR Surgical (NASDAQ:STAA – Get Free Report) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday, Zacks reports.
A number of other brokerages have also commented on STAA. UBS Group set a $34.00 price target on STAAR Surgical in a report on Thursday, November 5th. William Blair set a $33.00 price objective on shares of STAAR Surgical in a report on Thursday, August 13th. Jefferies Financial Group decreased their target price on shares of STAAR Surgical from $28.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, September 22nd. Stifel Nicolaus raised shares of STAAR Surgical from a “hold” rating to a “buy” rating and raised their target price for the company from $28.00 to $31.00 in a research note on Tuesday, September 29th. Finally, Wedbush dropped their price target on shares of STAAR Surgical from $40.00 to $37.00 and set an “outperform” rating on the stock in a research report on Thursday, August 13th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, STAAR Surgical presently has an average rating of “Hold” and a consensus price target of $29.00.
Read Our Latest Research Report on STAA
STAAR Surgical Trading Down 0.8%
STAAR Surgical (NASDAQ:STAA – Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.11 EPS for the quarter, beating the consensus estimate of $0.05 by $0.06. STAAR Surgical had a return on equity of 8.43% and a net margin of 0.16%. The firm had revenue of $83.41 million for the quarter, compared to analysts’ expectations of $78.73 million. During the same period last year, the firm earned $0.08 EPS. The firm’s revenue was down 11.9% compared to the same quarter last year. Sell-side analysts forecast that STAAR Surgical will post 0.43 earnings per share for the current fiscal year.
STAAR Surgical announced that its Board of Directors has authorized a stock buyback plan on Thursday, September 24th that permits the company to repurchase $50 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to reacquire up to 5.2% of its shares through open market purchases. Stock repurchase plans are typically an indication that the company’s management believes its shares are undervalued.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Zacks Investment Management raised its position in STAAR Surgical by 8.8% in the third quarter. Zacks Investment Management now owns 90,165 shares of the medical instruments supplier’s stock worth $2,039,000 after acquiring an additional 7,291 shares in the last quarter. Algert Global LLC bought a new position in shares of STAAR Surgical during the 3rd quarter valued at about $24,683,000. State of Tennessee Department of Treasury boosted its position in shares of STAAR Surgical by 10.8% during the 3rd quarter. State of Tennessee Department of Treasury now owns 16,384 shares of the medical instruments supplier’s stock valued at $370,000 after purchasing an additional 1,595 shares in the last quarter. Jump Financial LLC acquired a new position in shares of STAAR Surgical in the 3rd quarter worth approximately $380,000. Finally, EP Wealth Advisors LLC acquired a new position in shares of STAAR Surgical in the 3rd quarter worth approximately $473,000. 96.70% of the stock is owned by institutional investors and hedge funds.
STAAR Surgical Company Profile
STAAR Surgical is a medical device company focused on ophthalmic surgery and vision correction. The company develops, manufactures and markets implantable lenses and related products designed to reduce or eliminate dependence on glasses or contact lenses. Its principal product line is the EVO Visian Implantable Collamer Lens (ICL), a lens implanted inside the eye to correct myopia, with or without astigmatism. Unlike procedures that remove corneal tissue, ICL surgery preserves the eye’s natural lens and is designed to be removable.
See Also
- Five stocks we like better than STAAR Surgical
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
